NCT03979014View on ClinicalTrials.gov

Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Neoplasia
Interventions
BIOLOGICAL

Gardasill 9™ vaccine

3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month

Trial Locations (1)

SW7 2BT

Imperial College London, London

All Listed Sponsors
lead

Imperial College London

OTHER

NCT03979014 - Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial | Biotech Hunter | Biotech Hunter